MVST DEADLINE: Levi & Korsinsky Reminds Microvast Holdings, Inc. Investors of Upcoming Securities Class Action Deadline

Levi & Korsinsky, LLP notifies investors in Microvast Holdings, Inc. (NASDAQ: MVST) that a class action has been filed on behalf of shareholders who purchased securities between April 1, 2025 and March 16, 2026. MVST shares fell $0.79 per share, or 34.2%, to close at $1.52 on March 17, 2026, after Microvast reported Q4 2025 revenue of $96.5 million versus the $136.4 million consensus estimate and gross margin of 1.0%. Investors have until September 21, 2026 to seek lead plaintiff status. The securities action alleges that investor losses followed a sequence of Microvast timeline disclosure events, rather than a single isolated announcement. The complaint recounts that the Class Period opened with management projecting $450 million to $475 million in 2025 revenue, a 30% gross margin target, and first qualified production from the Huzhou Phase 3.2 expansion by Q4 2025. As detailed in the action, later events allegedly undermined those assurances. The lawsuit chronicles a short-seller report, an unexplained CFO departure, a delayed production timeline, and a final margin collapse tied to specialized ESS inventory that did not generate revenue during 2025. April 1, 2025: Microvast allegedly told investors that Huzhou Phase 3.2 capacity was expected online in Q4 2025 and that 2025 revenue guidance was $450 million to $475 million. June 25, 2025: Grizzly Research alleged that Microvast overstated business capabilities, Huzhou facility activity, and opportunities involving partnerships such as Gaussin. August 1 to August 4, 2025: Microvast announced that its CFO had departed after roughly three months, and MVST shares fell $0.30 per share, or approximately 9.93%, to $2.72. November 10 to November 11, 2025: Microvast stated that Huzhou Phase 3.2 initial production would begin in Q1 2026, and MVST shares fell $0.50 per share, or approximately 10%, to $4.48. March 16 to March 17, 2026: Microvast disclosed a $32.5 million inventory impairment, a Q4 gross margin decline to 1.0%, and a revenue miss, after which MVST shares fell 34.2%. The filing states that each event allegedly corrected part of Microvast’s prior public narrative about margins, customer demand, and manufacturing readiness. It is alleged that investors were not fully informed about inventory management issues and customer rollout delays affecting commercial vehicle platforms in EMEA. Timely disclosure of material developments is fundamental to fair and efficient markets. The alleged Microvast timeline matters because investors were told to expect capacity and margin progress before later announcements described delayed production, customer ramp issues, and a $32.5 million inventory impairment.